NRSNW · NeuroSense Therapeutics Ltd. · Shareholders & Ownership
Every disclosed holder of NRSNW in one list: 13F institutions, Schedule 13D and 13G filers, insiders (Forms 3, 4 and 5) and registered funds, each from its own latest filing. Holders nest by CIK and SEC reporting links, never by name, and each is summed once.
Who Owns NRSNW
13F quarter Jun 30, 2026; this listing alone: insiders and shares outstanding are issuer-wide, so they are left outNo chart: shares outstanding cannot be set against these holders.
| Holder group | Shares | % Out |
|---|---|---|
| Institutional (13F) | 164,650 | — |
| Insiders (Forms 3, 4, 5) | 0 | — |
| 13D/G-only blocks | 0 | — |
| Registered funds (N-PORT, not summed) | 0 | — |
% Out is unavailable: shares outstanding is an issuer-wide count, not one listing's.
13D/G-only counts each filer's latest 13D or 13G that no 13F report of the listing contains, that names no 13F filer and that no counted insider files. Funds are never summed: their shares sit inside their advisers' 13F reports.
Holders of NRSNW
| # | Holder | Shares | As of | Notes |
|---|---|---|---|---|
| 1 |
Empery Asset Management, LP
13F
CIK 1469336 · Registered investment adviser · Jun 30, 2026
|
100,402 | ||
| 2 |
Clear Street Group Inc.
13F
CIK 1881567 · Unknown · Jun 30, 2026
|
63,085 | ||
| 3 |
UBS Group AG
13F
CIK 1610520 · Bank · Jun 30, 2026
|
1,163 |
Shares are restated onto today's split basis. Change compares each row with the same holder's previous filing in the same source; a dash means there is none to compare. Nested 13D/G, insider and fund rows are not summed, since a 13F report already holds them.